Engflag

Pertuzumab

Quick links to important sections

Pertuzumab

Pertuzumab_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pertuzumab

Pertuzumab is a highly specialized targeted medicine used in the treatment of specific cancers. Its unique structure and function distinguish it within the class of HER2 inhibitors, offering a focused method of interfering with disease progression.

Property Description
Active ingredient Pertuzumab
Form Solution for intravenous infusion
Pharmacological Class Antineoplastic Agent, Monoclonal Antibody
General Purpose Inhibits cell growth signals via HER2 blockade
Origin Humanized, Recombinant DNA Technology

What Type of Medicine is Pertuzumab? (Classification and Identity)

Pertuzumab is classified as a humanized monoclonal antibody and is an antineoplastic agent within the high-level class of HER2 inhibitors. This positions it as a sophisticated form of targeted therapy, specifically engineered to interfere with highly selective biological processes driving the proliferation of certain abnormal cells. The active ingredient, Pertuzumab, is a complex protein produced using recombinant DNA technology.

This advanced manufacturing ensures a high degree of specificity for its molecular target. Its classification corresponds to the ATC code, L01FD02, which identifies its unique role among targeted agents that inhibit the Human Epidermal Growth Factor Receptor 2 (HER2).

Composition and General Therapeutic Purpose

The preparation centers on the single active ingredient, Pertuzumab, supplied as a sterile solution for intravenous infusion. This protein structure mandates delivery directly into the bloodstream via the intravenous route, distinguishing it from orally administered drugs. Pertuzumab is utilized in treatment strategies for HER2-positive conditions where the therapeutic goal is to stop excessive signaling pathways.

The overarching general purpose of Pertuzumab is to act as a HER2 dimerization inhibitor. By binding to a specific site on the HER2 receptor, the drug blocks the protein from pairing, or heterodimerizing, with its partners, which are essential for initiating growth signals within the cell. This strategic action, often part of a dual HER2 blockade, functions to suppress the activation of these growth pathways, providing a foundational effect by arresting cell proliferation driven by this specific HER2 pathway.

What side effects are possible with Pertuzumab?

Pertuzumab: Possible side effects and safety information

Serious Safety Warnings

Official regulatory documents include Boxed Warnings for two significant safety risks:

  • Left Ventricular Dysfunction (Cardiac Failure): Pertuzumab can cause subclinical or clinical cardiac failure, which may manifest as a decrease in the left ventricular ejection fraction (LVEF) and congestive heart failure. Heart function must be evaluated prior to and monitored during treatment. Treatment discontinuation is required for a confirmed clinically significant decrease in left ventricular function.
  • Embryo-Fetal Toxicity: Exposure to the medicine during pregnancy can lead to embryo-fetal death and birth defects. Pregnancy status must be verified prior to starting treatment. Females of reproductive potential are advised to use effective contraception during treatment and for a specified period (e.g., 7 months) following the last dose.

Other Clinically Significant Risks

Infusion-Related Reactions and Hypersensitivity Reactions/Anaphylaxis have been reported, including serious and fatal events. Patients are monitored closely during and after administration for signs and symptoms of these reactions, which may necessitate slowing or interrupting the infusion, or permanent discontinuation in the case of a severe reaction.

Very Common Adverse Reactions

The most common adverse reactions, reported with an incidence rate typically greater than 30% when Pertuzumab is administered in combination with trastuzumab and chemotherapy, often affect several organ systems, including:

System-Organ Class Very Common Adverse Reactions (Examples)
Gastrointestinal Diarrhea, Nausea, Vomiting
Skin and Subcutaneous Alopecia (hair loss), Rash
Blood and Lymphatic Neutropenia (low white blood cells)
General Disorders Fatigue, Peripheral Neuropathy

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory information for pertuzumab does not describe a specific overdose syndrome. The maximum tolerated dose is unknown, and no cases of overdose have been reported in the regulatory documentation. As such, the approach to a suspected overdose is framed around the immediate management of severe, life-threatening toxicities documented in the drug's label.

When to Seek Immediate Medical Help

Individuals must seek immediate medical attention for a suspected overdose or if symptoms of a severe reaction occur. The most critical documented risks requiring urgent intervention include anaphylaxis and severe hypersensitivity reactions. If such a severe or life-threatening reaction occurs, the regulatory mandate is the immediate and permanent discontinuation of the infusion, followed by the administration of appropriate medical therapies.

Overdose Management and Monitoring

In the absence of a specific antidote, treatment is symptomatic and supportive. A primary concern for overexposure is the potential for Left Ventricular Dysfunction (LVD). Regulatory rules require close observation and specific LVEF monitoring to determine if the dose must be withheld or permanently discontinued due to confirmed symptomatic heart failure. Additionally, no dose recommendations exist for patients with severe renal impairment due to limited data, which remains a consideration for overexposure management.

Therapeutic Uses of Pertuzumab

Pertuzumab is considered relevant in the therapeutic management of malignancies, primarily breast cancer, characterized by the biological characteristic of HER2 protein overexpression or gene amplification. This medication is applied across the full spectrum of HER2-positive disease, from early stage and locally advanced presentations to advanced metastatic disease, offering assistance in contexts involving heightened systemic burden for these specific conditions. The therapeutic use is relevant for managing symptoms that create noticeable physiological strain and supports patients during episodes of heightened discomfort. Pertuzumab is used strategically both before surgery (neoadjuvant setting) for managing conditions marked by increased physiological stress and after surgery (adjuvant setting) to support the patient during difficult episodes by easing distress, contributing to the overall therapeutic goal of supporting long-term disease control. It is commonly used in the initial management of advanced disease to support the patient during difficult episodes by easing distress and contributing to the goal of **maintaining functional stability.

Quick Fact: Relief for Physiological Strain

Regulatory References

  1. European Medicines Agency overview of Perjeta

Eligibility and Restrictions for Use

The eligibility for Pertuzumab (Perjeta) is strictly defined by regulatory documents, focusing primarily on patient health status and reproductive potential.

Eligibility Status Constraint / Condition
Contraindicated Known hypersensitivity or allergy to pertuzumab or any of its excipients.
Prohibited Pregnancy due to the risk of Embryo-Fetal Toxicity (fetal death and birth defects).
Conditional Pre-treatment Left Ventricular Ejection Fraction (LVEF) must be above a specific threshold (e.g., ge 50-55%) to initiate therapy. Use must be discontinued upon a confirmed clinically significant LVEF decrease.
Not Established Safety and efficacy have not been established for the pediatric population (< 18 years) or patients with severe renal impairment or hepatic impairment (due to limited data).

Females of reproductive potential must verify non-pregnancy status before initiation and are required to use effective contraception during treatment and for a specific period (e.g., seven months) after the last dose. Use in older adults (ge 65 years) requires no dose adjustment, but data is limited for those over 75 years of age.

Connection to the overall eligibility profile Official regulatory documents establish absolute non-eligibility for patients with hypersensitivity or who are pregnant, classifying these as contraindications. Eligibility is otherwise conditional upon demonstrating adequate baseline cardiac function, with strict protocols governing the continuation or discontinuation of the medicine based on LVEF monitoring. For specific groups like children and those with severe organ impairment, use is categorized as not established due to a lack of sufficient study data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Pertuzumab focuses on managing administration constraints and pharmacodynamic risks with co-administered oncology agents.

Interaction Scope and Risk Management

Category Official Regulatory Documentation Statement
Pharmacodynamic Interactions Co-administration with anthracycline-based regimens carries an expected increased risk of cardiac toxicity (Left Ventricular Dysfunction).
Exposure-Modifying Substances Regulatory studies confirmed no evidence of clinically relevant pharmacokinetic (PK) interactions between Pertuzumab and co-administered agents like Trastuzumab, Docetaxel, or other chemotherapies.
Timing-Based Rules Mandatory Timing Separation: Pertuzumab must be administered only following the completion of any entire anthracycline-based regimen to mitigate the documented cardiac risk.
Incompatibility Restriction Pertuzumab is subject to strict procedural rules that mandate it must not be mixed with any other medicinal product or diluted with a Dextrose (D5W) solution, requiring sequential infusion.

Population-Specific Interaction Notes

Regulatory documentation indicates limitations in data for specific patient groups. No specific dose recommendations can be made for patients with severe renal impairment due to limited pharmacokinetic data available in this population. Similarly, the safety and efficacy of Pertuzumab have not been studied in patients with hepatic impairment, precluding specific dose guidance.

No specific interaction warnings or restrictions concerning food, alcohol, or herbal products are formally documented in the official prescribing information.

Mechanism of Action

Targeting Receptor Dimerization (Dual Blockade)

Pertuzumab is a humanized monoclonal antibody designed to bind specifically to Extracellular Domain II of the HER2 receptor. This domain is essential for dimerization—the pairing of HER2 with other HER family receptors (like HER3), which creates the most potent unit for signal initiation. By binding here, pertuzumab acts as a steric inhibitor and physically prevents this pairing, thus restricting the pathway that conveys growth and survival signals to the cell.

Interruption of Intracellular Growth Signals

The blocked receptor complex fails to activate essential intracellular signal transduction pathways, primarily the PI3K/AKT/mTOR and MAP Kinase cascades. Non-activation of these pathways leads directly to two key physiological consequences: cell growth arrest (inhibition of proliferation) and the activation of the cell's self-destruct mechanism, known as apoptosis (programmed cell death).

Recruitment of Immune Cell Destruction (ADCC)

Beyond its direct signaling blockade, pertuzumab engages the immune system through Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). The antibody coats the targeted cell, enabling the binding and recruitment of immune effector cells, such as Natural Killer (NK) cells, to the cell surface. This combined action leads to the elimination of targeted cells, complementing the suppression of signaling pathways.

Dosage and Administration Information

How Pertuzumab is Used: Official Administration Guidelines

Pertuzumab is administered exclusively through intravenous (IV) infusion in a fixed, cycle-based regimen. It is supplied as a solution for infusion and must not be administered as a rapid IV push or bolus.

Dosing and Frequency

Treatment begins with a higher initial loading dose followed by lower, consistent maintenance doses given every three weeks. The dose is fixed and does not change based on a patient's body weight.

Administration Type Dose Infusion Time Frequency
Initial (Loading) Dose 840 mg 60 minutes Once
Subsequent (Maintenance) Dose 420 mg 30 to 60 minutes Every 3 weeks

Administration Protocol

Pertuzumab requires specific preparation and sequential administration. Before use, the correct amount of medicine is withdrawn from the single-use vial and diluted into a 250 mL bag of 0.9% sodium chloride (saline). It must not be mixed with other medications or 5% Dextrose solution.

The administration of Pertuzumab is typically part of a combination protocol and must be given sequentially with other agents. Specifically, the taxane chemotherapy component should be administered after both Pertuzumab and trastuzumab have been infused.

If a patient misses a scheduled infusion by six weeks or more, the 840 mg initial loading dose must be re-administered to restart the proper dosing cycle, followed by the 420 mg maintenance dose every three weeks.

Recent Clinical Evidence

Research evidence / Overview of studies for Pertuzumab

The research supporting the use of Pertuzumab was evaluated in large, international, controlled clinical trials known as Randomized Controlled Trials (RCTs). These studies compare the regimen that includes the agent against a standard regimen that includes a placebo. This approach allows researchers to monitor specific outcomes related to systemic or functional imbalance, such as how long patients remain healthy or the overall time they live, across defined study populations. The findings provide context but do not offer individual predictions, as study results reflect the specific conditions under which they were conducted.

Evidence for use in Metastatic Breast Cancer

Pertuzumab was studied for adults whose HER2-positive breast cancer had spread to other parts of the body (metastatic disease) and who had not received prior therapy for this advanced stage. Key research involved large RCTs comparing the regimen that included Pertuzumab against a regimen that included a placebo control. Researchers monitored Progression-Free Survival (PFS) and Overall Survival (OS). Studies examined and reported measurements of PFS and OS that was associated with the group receiving the regimen that included Pertuzumab. Follow-up for these pivotal trials has been exceptionally long-term, which contributes to the broader evidence landscape.

Evidence for use in Early Breast Cancer (Adjuvant Setting)

Following surgery, Pertuzumab was evaluated in a pivotal RCT involving adults with HER2-positive early breast cancer considered to be at high risk of recurrence. The main research aim was to measure Invasive Disease-Free Survival (iDFS), which is a composite measure including recurrence. Studies describe patterns observed in the studies, indicating that the difference in iDFS measurements was more evident in the research focused on the node-positive patient group. Evidence is limited for long-term outcomes in patients who did not have lymph node involvement (e.g., node-negative).

What is Still Uncertain About the Research Evidence

A key area of uncertainty is the reliance on short-term markers like Pathological Complete Response (pCR) in the neoadjuvant setting; pCR is a surrogate endpoint, and its exact correlation with long-term follow-up findings (such as Overall Survival) is a subject of continuing scientific discussion and an area where certainty remains low. Limitations in the research include that comparative evidence for all possible chemotherapy combinations is lacking, and follow-up durations were limited for some specialized data. Findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Pertuzumab (FAQ)

Q: What is the difference between Pertuzumab and Trastuzumab?

A: Pertuzumab and Trastuzumab are both targeted therapies that attach to the HER2 receptor, but they bind to different sites. Pertuzumab specifically binds to a site that blocks the HER2 receptor from pairing with its partners (a process called dimerization). Regulatory studies indicate that combining these two agents is intended to provide a more comprehensive blockade of the HER signaling pathway, augmenting their individual anti-tumor activity.

Q: Why is Pertuzumab often given with other drugs?

A: Pertuzumab is only approved and indicated for use in combination with trastuzumab and a chemotherapy agent, such as docetaxel. Regulatory studies supporting its use indicate that combining Pertuzumab with these agents is associated with augmented anti-tumor activity, which forms the basis for this combination protocol.

Q: What is the difference between Pertuzumab and other HER2 inhibitors?

A: Pertuzumab is specifically classified as a HER2 dimerization inhibitor. This means its primary function is to prevent the HER2 protein from pairing up with other receptors, which is a necessary step for initiating powerful cell growth signals. This unique mechanism is what distinguishes it within the broader class of HER2-targeting medicines.

Q: What are the rare but serious side effects of Pertuzumab?

A: Official product information contains Boxed Warnings for two significant risks: Left Ventricular Dysfunction (a form of heart failure) and Embryo-Fetal Toxicity (potential harm to an unborn baby). Other serious risks include Infusion-Related Reactions and severe Hypersensitivity Reactions (like anaphylaxis), which are monitored closely during administration.

Q: Is Pertuzumab used only for breast cancer?

A: Regulatory bodies have indicated and approved Pertuzumab only for the treatment of specific types of HER2-positive breast cancer. This includes treatment for advanced (metastatic) disease, as well as treatment given before (neoadjuvant) and after (adjuvant) surgery for earlier-stage disease.

Q: What is the brand name of Pertuzumab?

A: The brand name for the medicine containing the active ingredient pertuzumab is Perjeta.

Q: What should I do if I miss an appointment for my Pertuzumab infusion?

A: Official administration guidelines outline a protocol for missed infusions, which may involve re-administering the initial higher loading dose if a significant amount of time has passed. For example, if a treatment is delayed by six weeks or more, the protocol specifies that the cycle must be restarted by giving the initial higher dose.

Q: Is it normal to feel very tired after a Pertuzumab treatment?

A: Yes, fatigue is listed in regulatory documents as a Very Common Adverse Reaction when this medicine is given in combination protocols. Official product information notes that fatigue is a Very Common Adverse Reaction when the medicine is given in combination protocols.

Q: Does Pertuzumab require a port for administration?

A: Pertuzumab is administered exclusively through intravenous (IV) infusion, meaning it is delivered directly into a vein. While the regulatory documents require the IV route, they do not specifically mandate the use of a vascular access port.

Q: How does Pertuzumab target the HER2 receptor?

A: Pertuzumab is an antibody that is designed to specifically target and bind to Extracellular Domain II of the HER2 receptor. This binding physically blocks the receptor from partnering with other receptors, thereby inhibiting the signal that initiates cell growth and survival.

Q: What clinical trials led to the approval of Pertuzumab?

A: Key clinical evidence that led to approval came from large, international studies. For metastatic breast cancer, the pivotal trial was CLEOPATRA. For neoadjuvant (pre-surgery) treatment, evidence was largely based on studies like NeoSphere.

Q: What is the typical monitoring schedule while on Pertuzumab (e.g., blood tests)?

A: Due to the potential for cardiac effects, heart function, specifically the Left Ventricular Ejection Fraction (LVEF), must be carefully evaluated before treatment and monitored at regular intervals during the course of therapy. The potential for common adverse reactions like Neutropenia (low white blood cells) may necessitate additional monitoring, such as blood tests.

Q: What happens if Pertuzumab treatment is stopped suddenly?

A: Treatment is typically discontinued only if a patient develops a confirmed, clinically significant decrease in their LVEF (heart function). Official guidance states that if the accompanying chemotherapy agent is discontinued, treatment with pertuzumab and trastuzumab may often continue.

Q: Is Pertuzumab an antibody-drug conjugate?

A: No, Pertuzumab is classified as a humanized monoclonal antibody. It is a protein designed to block a specific pathway. It is not an antibody-drug conjugate, which is a type of medicine that links a toxic chemotherapy agent directly to an antibody.

Q: Why do some people experience infusion-related reactions with Pertuzumab?

A: Infusion-related reactions and hypersensitivity are known risks associated with the administration of antibody-based medicines like Pertuzumab. Regulatory documents indicate these reactions, including fever and chills, are a potential occurrence, and patients are closely observed during and after their infusion.

Q: Does Pertuzumab affect fertility in men or women?

A: The primary safety concern noted in regulatory documents is the risk of Embryo-Fetal Toxicity (harm to a fetus). Because of this risk, females of reproductive potential are required to use effective contraception during treatment and for a specified period after the last dose. No specific warnings about permanent fertility impairment are detailed in the official prescribing information.

Q: How long does Pertuzumab stay in the body after the last dose?

A: According to pharmacokinetic studies, which track how the body processes the medicine, Pertuzumab has a relatively long elimination time. The terminal elimination half-life is approximately 18 days.

Q: Do older patients respond differently to Pertuzumab than younger patients?

A: Official data indicate that, generally, no dose adjustment is necessary for older patients, including those up to 75 years of age. Clinical studies found that no dose adjustment is generally necessary for older patients and no significant differences in safety were observed between patients aged 65 to 75 years and those under 65 years.

Q: What are the long-term effects of Pertuzumab treatment?

A: The most significant long-term risk highlighted in the regulatory Boxed Warning is the potential for Left Ventricular Dysfunction (Cardiac Failure). This risk requires continuous heart monitoring before and during treatment.

Q: What type of cancer cells is Pertuzumab ineffective against?

A: Pertuzumab is a highly targeted medicine approved only for HER2-positive cancer cells. Since it is a targeted medicine, Pertuzumab is not approved or indicated for treating cancer cells that are HER2-negative or those that do not use the HER2 pathway for growth.

Q: How is the effectiveness of Pertuzumab measured?

A: In the large clinical trials that supported approval, the effectiveness of the regimen was typically measured using outcomes like Progression-Free Survival (PFS) and Overall Survival (OS) for advanced disease, or the rate of Pathological Complete Response (pCR) for pre-surgery treatment.

Q: Is it possible to become resistant to Pertuzumab over time?

A: While resistance is a topic of scientific research, some clinical trial data supported the use of Pertuzumab in patients whose disease had progressed while on prior trastuzumab-containing therapy. Official regulatory documents do not provide a general statement on the probability or mechanism of acquired resistance.

Q: What are common patient experiences during a Pertuzumab infusion?

A: Infusion-related reactions are common, and regulatory documents list experiences such as fever (pyrexia), chills, fatigue, headache, and weakness (asthenia) as those most frequently reported during or shortly after the infusion.

Q: Are there generic versions of Pertuzumab available?

A: As Pertuzumab is a complex biological medicine, regulatory bodies have approved biosimilar versions, which are highly similar to the original product.

Q: Is it normal to have mild flu-like symptoms after a Pertuzumab infusion?

A: Yes, symptoms often described as flu-like can be common infusion-related reactions. Official safety information lists common reactions such as fever (pyrexia), chills, and headache that occur during or after the infusion.

How should Pertuzumab be stored and disposed of?

Storage and Disposal of Pertuzumab

Storage of unopened pertuzumab vials requires strict temperature control. Vials must be stored in a refrigerator at temperatures between 2 C and 8 C (36 F to 46 F), and they must not be frozen.

Handling and Stability

The vial must be kept in its original carton to ensure protection from light. Pertuzumab should be stored out of the sight and reach of children.

Once the solution is diluted for infusion, it is stable for up to 24 hours at 2 C to 8 C.

Disposal

Any unused portion of the product remaining in the vial must be discarded. Disposal of the medicine and related waste must follow local and national regulations for pharmaceutical waste, and the product should not be disposed of via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pertuzumab found in:

A-Z Index: